Cytology smears in the era of molecular biomarkers in non–small cell lung cancer: doing more with less
MD Lozano, JI Echeveste… - … of pathology & …, 2018 - meridian.allenpress.com
Context.—The rapid advances in targeted therapies in non–small cell lung cancer (NSCLC)
make the optimization and implementation of cytology specimens for molecular testing a …
make the optimization and implementation of cytology specimens for molecular testing a …
[HTML][HTML] Direct identification of ALK and ROS1 fusions in non-small cell lung cancer from hematoxylin and eosin-stained slides using deep learning algorithms
C Mayer, E Ofek, DE Fridrich, Y Molchanov, R Yacobi… - Modern Pathology, 2022 - Elsevier
Anaplastic lymphoma kinase (ALK) and ROS oncogene 1 (ROS1) gene fusions are well-
established key players in non-small cell lung cancer (NSCLC). Although their frequency is …
established key players in non-small cell lung cancer (NSCLC). Although their frequency is …
[HTML][HTML] Pharmacovigilance analysis of cardiac toxicities associated with targeted therapies for metastatic NSCLC
Introduction Targeted therapies have transformed treatment of driver-mutated metastatic
NSCLC. We compared cardiovascular adverse events between and within targeted therapy …
NSCLC. We compared cardiovascular adverse events between and within targeted therapy …
[HTML][HTML] Understanding the feasibility of chemotherapeutic and immunotherapeutic targets against non-small cell lung cancers: an update of resistant responses and …
Despite consistent progress in prompt diagnosis and curative therapies in the last decade,
lung cancer (LC) continues to threaten mankind, accounting for nearly twice the casualties …
lung cancer (LC) continues to threaten mankind, accounting for nearly twice the casualties …
Counteracting lineage-specific transcription factor network finely tunes lung adeno-to-squamous transdifferentiation through remodeling tumor immune …
Human lung adenosquamous cell carcinoma (LUAS), containing both adenomatous and
squamous pathologies, harbors strong plasticity and is significantly associated with poor …
squamous pathologies, harbors strong plasticity and is significantly associated with poor …
EML4-ALK fusions drive lung adeno-to-squamous transition through JAK-STAT activation
Human lung adenosquamous cell carcinoma (LUAS), containing both adenomatous and
squamous pathologies, exhibits strong cancer plasticity. We find that ALK rearrangement is …
squamous pathologies, exhibits strong cancer plasticity. We find that ALK rearrangement is …
Feasibility of endobronchial ultrasound-guided transbronchial needle aspiration cytology specimens for next generation sequencing in non–small-cell lung cancer
SP Stoy, JP Segal, J Mueller, LV Furtado, EE Vokes… - Clinical Lung Cancer, 2018 - Elsevier
Introduction Next generation sequencing (NGS) testing of lung cancer is recommended by
guidelines, and endobronchial ultrasound (EBUS)-guided transbronchial needle aspiration …
guidelines, and endobronchial ultrasound (EBUS)-guided transbronchial needle aspiration …
Circular RNA hsa_circ_0001588 promotes the malignant progression of lung adenocarcinoma by modulating miR-524-3p/NACC1 signaling
Z Sun - Life Sciences, 2020 - Elsevier
Aims Previous studies have demonstrated that circular RNAs play significant roles in several
tumors, including lung adenocarcinoma; however, specific biological functions and …
tumors, including lung adenocarcinoma; however, specific biological functions and …
[HTML][HTML] Oncogenic ALK regulates EMT in non-small cell lung carcinoma through repression of the epithelial splicing regulatory protein 1
A subset of Non-Small Cell Lung Carcinoma (NSCLC) carries chromosomal rearrangements
involving the Anaplastic Lymphoma Kinase (ALK) gene. ALK-rearranged NSCLC are …
involving the Anaplastic Lymphoma Kinase (ALK) gene. ALK-rearranged NSCLC are …
Comparative efficacy and safety of first-line treatments for advanced non-small cell lung cancer with ALK-rearranged: a meta-analysis of clinical trials
H Ma, Y Liu, K Ding, Y Liu, W Zhao, Y Zhu, X Chang… - BMC cancer, 2021 - Springer
Background Whereas there are many pharmacological interventions prescribed for patients
with advanced anaplastic lymphoma kinase (ALK)-rearranged non-small cell lung cancer …
with advanced anaplastic lymphoma kinase (ALK)-rearranged non-small cell lung cancer …